Filing Flows › Anika Therapeutics (ANIK) › Q2 2025
Anika Therapeutics (ANIK) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 30, 2025
Anika Therapeutics (ANIK) reported revenue of $28.2M for the second quarter 2025 (Q2 2025), -8% from a year earlier and +8% from the quarter before. Operating margin was -14.8%, net loss $4.0M (14.1% of revenue).
Anika Therapeutics, Q2 2025: revenue $28.2M (-8% year over year), operating margin -14.8%, net loss $4.0M, operating cash flow −$189K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.2M | +8% | -8% |
| Operating profit | −$4.2M | — | — |
| Net earnings | −$4.0M | — | — |
| Operating cash flow | −$189K | — | — |
What changed
Revenue was $28.2M in Q2 2025, down 8% year over year and up 8% from the previous quarter. OEM Channel was the largest line at 58% of revenue. OEM Channel lost $2.5M year over year (down 13%), 102% of the total change.
Gross margin was 50.9%, down 15.8 points from a year earlier. Operating costs exceeded revenue by $4.2M, an operating margin of -14.8%. Operating expenses fell 17% while revenue fell 8%. The quarter ended with a net loss of $4.0M, narrower than the previous quarter's $4.9M loss. Non-operating items added $891K, -27% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$189K. Non-cash charges added back $1.3M of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $47K. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$1.7M.
Questions
What was Anika Therapeutics' revenue in the second quarter 2025?
Anika Therapeutics (ANIK) reported revenue of $28.2M for the second quarter 2025 (Q2 2025), -8% from a year earlier and +8% from the quarter before.
Was Anika Therapeutics profitable in the second quarter 2025?
Operating loss was $4.2M (-14.8% of revenue) and net loss $4.0M.
Source: Anika Therapeutics 10-Q on SEC EDGAR.